Neither mycophenolate acyl-glucuronide levels nor their areas under the curve are responsible for the gastrointestinal side effects in kidney transplant recipients receiving EC-MPA: a prospective trial.

[1]  Yi-ping Lu,et al.  [Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil]. , 2009, Zhonghua yi xue za zhi.

[2]  C. Guillemette,et al.  Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. , 2008, Pharmacogenomics.

[3]  R. Levy,et al.  Pharmacokinetics of Mycophenolic Acid and its Phenolic – Glucuronide and Acyl Glucuronide Metabolites in Stable Thoracic Transplant Recipients , 2008 .

[4]  Cynthia Balion,et al.  Utility of monitoring mycophenolic acid in solid organ transplant patients. , 2008, Evidence report/technology assessment.

[5]  N. Davies,et al.  Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  D. Kuypers,et al.  The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide , 2007, Transplantation.

[7]  V. Armstrong,et al.  Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients , 2006, Clinical pharmacology and therapeutics.

[8]  H. Muller,et al.  THERAPEUTIC DRUG MONITORING OF MYCOPHENOLIC ACID IN KIDNEY TRANSPLANT PATIENTS. AN ABBREVIATED SAMPLING STRATEGY. , 2006, Transplantation proceedings.

[9]  A. Bensman,et al.  Population Pharmacokinetics of Mycophenolic Acid in Kidney Transplant Pediatric and Adolescent Patients , 2005, Therapeutic drug monitoring.

[10]  V. Armstrong,et al.  Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? , 2000, Clinical biochemistry.

[11]  V. Armstrong,et al.  Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. , 1999, Clinical chemistry.

[12]  J. Williams,et al.  Gastrointestinal Quality of Life Index: Development, validation and application of a new instrument , 1995, The British journal of surgery.

[13]  I. Wiklund,et al.  Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease , 2004, Quality of Life Research.

[14]  J. Squifflet,et al.  Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. , 2001, Clinical chemistry.